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P
arkinson disease (PD) is the most common 
neurodegenerative movement disorder in humans, but 
its cause in the majority of patients is unknown. Fewer 
than 10% of cases appear to be inherited, and only rarely are 
the known Mendelian mutations identiﬁed in patients with 
PD. In addition to genetic factors, environmental toxins—
especially those affecting mitochondrial function—have 
also been implicated [1,2], demonstrating a clear role for 
gene–environment interactions in most cases of sporadic PD. 
Patients afﬂicted with PD experience slow, selective, often 
asymmetric loss of dopaminergic (DA) neurons projecting 
from the substantia nigra (SN) to the striatum, but not of 
DA neurons located elsewhere in the brain (e.g., ventral 
tegmental area and retina). Once more than 80%–90% of DA 
neurons in the SN are lost, patients suffer the characteristic 
symptoms of tremor, slow movements (bradykinesia), rigidity, 
and postural instability.
To study PD, researchers have used two basic types of 
animal models: (1) acute lesioning of DA neurons/tracts, 
either by surgery or toxic insult, and (2) genetic models 
that rely on expression of one of the rare, dominant, and 
highly penetrant mutations that cause PD or knockout of a 
similar, recessively inherited allele (e.g., A-synuclein, Parkin, 
and leucine-rich repeat kinase-2 [LRRK2]). Although these 
models have led to huge advances in our understanding 
of PD—implicating mitochondrial dysfunction, oxidative 
damage, and protein handling systems in pathogenesis—they 
typically either fail to recapitulate the gradual nature of 
this degenerative disease or lack the deﬁning pathology 
(e.g., Parkin and A-synuclein transgenic mice fail to show 
progressive nigrostriatal degeneration, although rotenone-
treated mice do show Lewy bodies (intracytoplasmic 
inclusions that are composed primarily of A-synuclein
and ubiqutin)) [3,4]. Because no single animal model is 
likely to be sufﬁcient for the study of any particular human 
neurodegenerative disease, new models are needed to 
accelerate our ability to devise and test improved disease-
altering therapies.
It is in this regard that a new paper in PLoS Biology 
by Kittappa et al. [5] warrants special attention. They 
demonstrate that knockout of a transcription factor FoxA2, 
which is critical for DA neuron speciﬁcation and survival in 
mice causes a late-onset, asymmetric degenerative condition 
affecting motor systems in a manner very similar to PD. This 
model is entirely distinct in its basic mechanism from the 
aforementioned models, because it involves partial loss of a 
transcription factor that is critical for DA neuron cell fate. 
One of the most striking features of the majority of adult-
onset neurodegenerative diseases is their regional or cell-
type speciﬁcity in humans. Yet, many of the known causative 
mutations reside in proteins that are widely expressed 
throughout the central nervous system, such as synuclein, 
LRK2, and Parkin in PD, beta amyloid and presenilin-1 
(PS1) in Alzheimer disease, and tau and progranulin in 
frontotemporal dementia. The current study in mice, and 
previous work in humans and other model organisms, 
highlight the potential role that neurodevelopmental factors 
may play in the cell-type–speciﬁc or regional neuronal 
vulnerability seen in neurodegenerative disease [6,7] 
As this work by Kittappa and colleagues demonstrates, 
understanding early developmental processes such as cell-type 
speciﬁcation and survival may have major implications for 
aging-related diseases.
Development of Nigral DA Neurons 
Dopamine neurons are initially generated in a permissive 
region at the embryonic midbrain–hindbrain border 
(isthmus). This region is formed by intersecting gradients of 
several molecules: ﬁbroblast growth factor-8 (FGF8), which 
is produced by cells at the isthmus, secreted sonic hedgehog 
(Shh) from the ventral neural tube and ﬂoorplate, and Wnt-
1 and Wnt5a from the midbrain and rostral diencephalons.. 
These factors induce a proneuronal program in dividing 
neuroepithelial precursors that speciﬁcally favors DA 
differentiation and concomitantly suppresses differentiation 
in non-DA neurons (reviewed in[8]). The anatomic 
distribution of these factors is illustrated in Figure 1.
Two recent studies show that Shh and FoxA1/2 are 
required for differentiation of both DA neurons and the 
serotonergic (5HT) neurons [9,10]. Interestingly, these 
studies suggest that both Shh and FoxA2 are able to induce 
the other’s expression. Kittappa et al., unravel some of the 
complexity of this interaction. They demonstrate that Shh-
induced FoxA2 expression is responsible for driving the 
DA differentiation program. However, FoxA2 also induces 
continued Shh expression, which can drive proliferation of 
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uncommitted progenitors, promoting their survival once 
differentiated [11]. Deﬁning an initiating role for FoxA2 is 
good news for the production of DA neurons from embryonic 
stem (ES) cells, but previous studies left open the intriguing 
question of what role FoxA2 plays in the functioning of adult 
DA neurons.
A New Mouse Model of PD That Connects 
Development with Adult Neurodegeneration
 The article by Kittappa et al. [5] highlights two important 
ﬁndings that could change the terrain for investigating the 
etiology of PD. As mentioned above, the authors clarify 
the developmental origins of DA neurons and establish a 
framework of transcription factors that provides a context 
for the experimental regulation of midbrain neuron 
differentiation. Second, they report a highly unique age-
dependent onset of DA cell loss, which begins asymmetrically 
in the brain.
Because FoxA2-null mutants die prenatally, Kittappa et 
al. explored the effects of missing just one copy of FoxA2 
(haploinsufﬁciency) in aging heterozygous FoxA2+/– mice.
These mice show no gross histological or behavioral 
abnormalities throughout most of their life, but when the 
mice are in late adulthood (18 mo old), the researchers 
observed that approximately one-third of animals begin 
to develop progressive muscle rigidity with asymmetric 
posturing and tremors, not seen in age-matched wild-type 
littermates. These symptoms, which are suggestive of striatal 
degeneration, prompted the authors to demonstrate a 
functional lesion of the dopaminergic system using the 
standard amphetamine-induced rotation assay. Affected 
animals showed signiﬁcant, asymmetric loss of DA neurons in 
the SN, particularly among retinoic acid–producing neurons, 
but the animals showed no loss in the ventral tegmental 
area. In contrast, age-matched FoxA2+/– mice that displayed 
a normal behavioral phenotype had no attendant loss of DA 
neurons. Interestingly, affected animals exhibited bilateral 
activation of astrocytes in multiple midbrain areas, suggesting 
that some effects of haploinsufﬁciency may be more diffuse. 
Together, these ﬁndings demonstrate that the authors 
have generated a new animal model of PD that captures both 
the late onset and selectivity of dopaminergic degeneration, 
including asymmetric motor dysfunction, which is a hallmark 
of the disorder in humans. However, one cardinal pathologic 
feature of PD not observed in this model is the presence of 
Lewy bodies [12]. Although Lewy bodies are still considered a 
pathological feature of PD, they are not a sine qua non for the 
disease. Many patients, including patients harboring PARK2 
(Parkin) mutations, lack extensive Lewy body pathology on 
autopsy yet exhibit all the clinical features of PD [13,14]. 
FoxA2 Presents New Opportunities for PD Research
The present study raises a host of interesting questions. 
First, why does FoxA2 haploinsufﬁciency lead to progressive 
loss of DA neurons and their projections to the striatum? 
Although detailed studies will be required to properly 
answer this question, one can hypothesize that loss of FoxA2 
may be required for proper target innervation; when these 
projections recede, target-derived trophic support is lost [15]. 
Evidence supporting this speculation comes from studies 
showing that FoxA2 targets may include genes involved with 
target innervation and survival of DA neurons [16,17].
Can these exciting ﬁndings be extrapolated to better our 
understanding of human PD or prove useful to developing 
ways of treating this disease? The ﬁdelity with which this 
animal model seems to parallel several key aspects of PD in 
humans tempts one to speculate that some forms of PD may 
arise through dysfunction of FoxA2. Thus, FoxA2 and its 
targets are candidates for genetic association studies in PD 
in humans. Additionally, given the chronicity and late onset 
observed in the heterozygous mice, as well as the incomplete 
penetrance at 18 months, these mice provide an exciting 
opportunity to investigate gene-gene and gene-environment
interactions that may affect DA neuron survival in vivo. 
Based on these ﬁndings, one may also propose that 
overexpression of FoxA2 could be used to drive DA 
differentiation of implanted neural stem cells for use in 
neural repair paradigms in humans with PD. It will also be 
worthwhile to explore whether increasing FoxA2 protein 
dosage, by vector-mediated overexpression of FoxA2, is 
neuroprotective against other genetic or environmental 
lesions of the nigral DA neuron population.  At the same 
time, we need to recognize that these proposals rely on the 
assumption that FoxA2 will have the same subset of critical 
targets in human tissue as it does in mouse. Fraenkel and 
colleagues [18] analyzed the conservation of FoxA2 binding 
in mouse versus human hepatocytes. Surprisingly, they 
found that while FoxA2 bound nearly 600 mouse genes, only 
11% of these were also bound in humans. Since promoter 
binding is state dependent and binding does not necessarily 
entail transcriptional activity, further study will be needed 
doi:10.1371/journal.pbio.0050334.g001
Figure 1. Factors inﬂuencing monoaminergic cell development in 
regions of FoxA2 expression 
Schematic of brain, approximately E8-11.  At earlier stages (not 
shown), Lmx1b, Wnt1, Grg4, Otx2, and Gbx2 set up complex parallel 
feedback loops that establish the FGF8 secreting isthmus organizer at 
the midbrain–hindbrain boundary. Shown here, at later stages, Otx2 
represses Nkx2.2 expression in the mesodiencephalon. Shh, which 
is produced by cells of the ﬂoor plate and notochord, induces FoxA2 
expression in the rhombencephalon (hindbrain), mesencephalon 
(midbrain), and caudal prosencephalon (dielcephalon). DA neurons are 
formed in those regions of FoxA2 expression where Nkx2.2 is repressed. 
Nine groups of dopaminergic neurons are formed in the forebrain and 
midbrain. Only groups A8–10 are shown. A8/9 cells give rise to the SN, 
whereas A10 cells eventually comprise the ventral tegmental area (VTN). 
Prosomeres, P1–P6; rhombmeres, R1–R7; serotonergic cells, B1–B9; DA 
cells, A8–A10.  Figure is adapted from [8,19–21]
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to understand the appropriate parallels between mouse and 
human FoxA2 in the DA cells of relevance to PD. In spite of 
these uncertainties, this new paper provides an entirely fresh 
perspective on DA neuron survival and a powerful new animal 
model in which to test gene–environment interactions and 
new therapeutic approaches in PD.  
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